Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NCT07109726 is registered in ClinicalTrials.gov with Terremoto Biosciences Inc. as lead sponsor.

NCT NCT07109726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Lead sponsor
Terremoto Biosciences Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 23, 2025
Completion date
February 28, 2029
Enrollment
205 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, endometrial cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, lung squamous cell carcinoma, ovarian cancer, solid tumor